Given our data comparing the tumor penetration of an anti-PDL1 antibody versus St-PGA-OG-mUNO, anti-CD163 systems may also display lower tumor accumulation than St-PGA-OG-mUNO and OximUNO. This evidence concerns the gene CD163 and neoplasm.